- Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories
- Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month
- Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month
- Axsome Therapeutics to Participate in Upcoming Investor Conferences
- Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024
- Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) Meeting
- Axsome Therapeutics to Present at Upcoming Investor Conferences
- Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
- Axsome Therapeutics Recognizes May as Mental Health Awareness Month
- Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
More ▼
Key statistics
As of last trade Axsome Therapeutics Inc (AXSM:NMQ) traded at 82.00, -16.67% below its 52-week high of 98.40, set on Feb 12, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 79.95 |
---|---|
High | 82.06 |
Low | 79.73 |
Bid | 81.94 |
Offer | 82.10 |
Previous close | 80.21 |
Average volume | 799.76k |
---|---|
Shares outstanding | 47.50m |
Free float | 38.30m |
P/E (TTM) | -- |
Market cap | 3.81bn USD |
EPS (TTM) | -6.38 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 20:25 BST.
More ▼